Abstract
AbstractTo compare baseline characteristics, initial response and 12-month efficacy and safety outcomes in eyes with branch and central retinal vein occlusion (BRVO and CRVO) treated with dexamethasone implants (DEX) or anti-vascular endothelial growth factor (anti-VEGF) we performed a multi-centre, retrospective and observational study using Fight Retinal Blindness! Registry. Of 725 eligible eyes, 10% received DEX initially with very frequent adjunctive anti-VEGF (BRVO-DEX 49%, CRVO-DEX 60%). The primary outcome of mean adjusted change in VA at 12 months with DEX and anti-VEGF initiated groups were not statistically significantly different (BRVO: DEX + 6.7, anti-VEGF + 10.6 letters; CRVO: DEX + 2.8, anti-VEGF + 6.8 letters). DEX initiated eyes had fewer injections and visits than anti-VEGF initiated eyes. The BRVO-DEX eyes had greater initial mean changes in VA and central subfield thickness (CST) and achieved inactivity sooner than BRVO-anti-VEGF eyes. The mean CST after the first three months was above 350 μm in all but the BRVO-anti-VEGF group, suggesting undertreatment. In routine care DEX is uncommonly used when available as initial treatment of BRVO and CRVO requiring supplemental anti-VEGF within the first year. The 12-month outcomes were similar, but DEX initiated eyes had fewer injections and visits but more episodes of raised IOP Vs those starting anti-VEGF.
Publisher
Springer Science and Business Media LLC
Reference37 articles.
1. Qiu, X. Y. et al. Comparison of intravitreal aflibercept and dexamethasone implant in the treatment of macular edema associated with diabetic retinopathy or retinal vein occlusion: A meta-analysis and systematic review. Int. J. Ophthalmol. 15(9), 1511–1519 (2022).
2. Nicholson, L., Talks, S. J., Amoaku, W., Talks, K. & Sivaprasad, S. Retinal vein occlusion (RVO) guideline: Executive summary. Eye. 36(5), 909–912. https://doi.org/10.1038/s41433-022-02007-4 (2022).
3. Buehl, W., Sacu, S. & Schmidt-Erfurth, U. Retinal vein occlusions. In Developments in Ophthalmology Vol. 46 (eds Bandello, F., Battaglia Parodi, M., Augustin, A. J. et al.) 54–72 (S. Karger AG, 2010).
4. Flaxel, C. J. et al. Retinal vein occlusions preferred practice pattern®. Ophthalmology. 127(2), P288–P320 (2020).
5. Hayreh, S. S. Retinal vein occlusion. Indian J. Ophthalmol. 42(3), 109–132 (1994).